Migraine firm wants to eliminate doubt about new product - raises USD 2.8 million for new clinical trial

Medtech company Balancair has raised DKK 19 million (USD 2.8 million) from investors, primarily to finance a clinical trial with over 150 migraine patients from several countries. It hopes that this will eliminate cricitism of the results from the firm's earlier pilot study.

Asger Hee Stjernholm, CEO of migraine company Balancair Photo: BalancAir/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles